Sort   by:  
 Page size 
ProteomicsAdherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro-inflammatory tumor microenvironment in esophageal adenocarcinoma
Esophageal adenocarcinomas represent aggressive gastrointestinal malignancies, characterized by poor survival and variable responses to perioperative therapies. Our study identified a significant association between adherens junction (AJ) protein expression and treatment response to FLOT chemotherap...
ORGANISM(S): Homo sapiens (Human) 
2026-01-06 | PXD071328 | Pride
Esophageal adenocarcinoma Flot perioperative treatment Cell adhesion Tumor microenvironment 
UnknownTreatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO).
Not available
S-EPMC12260966 | biostudies-literature
UnknownPerioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Not available
S-EPMC9097175 | biostudies-literature
UnknownAn Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers.
Not available
S-EPMC9718608 | biostudies-literature
UnknownReal-World Outcomes Between Perioperative Chemotherapy (FLOT) and Preoperative Concurrent Chemoradiotherapy (CROSS) in Localized Esophageal and Esophagogastric Junction Adenocarcinoma: A Retrospective Cohort Study.
Not available
S-EPMC12468997 | biostudies-literature
UnknownReal-World Outcomes for Localised Gastro-Oesophageal Adenocarcinoma Cancer Treated with Perioperative FLOT and Prophylactic GCSF Support in a Single Asian Centre.
Not available
S-EPMC11545039 | biostudies-literature
UnknownEconomic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Not available
S-EPMC9664295 | biostudies-literature
UnknownPembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).
Not available
S-EPMC10615128 | biostudies-literature
UnknownPattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Not available
S-EPMC10356632 | biostudies-literature
UnknownESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Not available
S-EPMC4952147 | biostudies-literature
Sort   by:  
 Page size